Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. (VIR) pioneers immunology solutions targeting complex infectious diseases through innovative platforms including antibody therapies, T cell engineering, and siRNA technology. This dedicated news hub provides investors and industry stakeholders with timely updates on clinical developments, strategic partnerships, and regulatory milestones.
Access authoritative updates on VIR's research pipeline, financial performance announcements, and scientific breakthroughs in infectious disease management. Our curated collection ensures transparent access to press releases spanning clinical trial progress, collaborative initiatives, and patent filings.
Key updates include advancements in hepatitis B/HIV therapies, influenza A research, and platform technology licensing agreements. Bookmark this page to efficiently monitor VIR's contributions to biotechnology and its evolving position in global health innovation.
Vir Biotechnology will host a virtual presentation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 11:00 am PT / 2:00 pm ET. The presentation will be led by Phil Pang, M.D., Ph.D., the chief medical officer of Vir. Interested parties can access the live webcast on the Investors section of their website, www.vir.bio, which will be available for 30 days post-event. Vir focuses on treating serious infectious diseases using advanced immunological technologies.
Vir Biotechnology, Inc. (Nasdaq: VIR) appointed Janet Napolitano to its board of directors, bringing extensive leadership experience from both public and private sectors. Napolitano previously served as Arizona's Governor and U.S. Secretary of Homeland Security, and was President of the University of California for seven years. She replaces Kristina Burow, a founding director essential to the company’s early growth. Napolitano aims to support Vir's mission to address global infectious diseases, aligning with her public health passions.
Vir Biotechnology announced the initiation of the Phase 2/3 COMET-ICE study for VIR-7831, a monoclonal antibody aimed at preventing COVID-19 hospitalizations in high-risk patients. The study will enroll approximately 1,300 participants, with initial results expected by the end of 2020 and full results in Q1 2021. If successful, VIR-7831 may be available for early access in mid-2021. This trial follows a collaboration with GlaxoSmithKline to develop treatments for coronaviruses, leveraging Vir's antibody platform to identify effective antiviral candidates.
Vir Biotechnology reported financial results for Q2 2020, showing revenues of $67.0 million, up from $2.0 million in Q2 2019, driven by significant licensing agreements. The company plans to initiate a Phase 2/3 trial for VIR-7831, a monoclonal antibody targeting SARS-CoV-2, in August, with initial data expected by year-end. R&D expenses rose to $79.7 million due to increased activity in clinical trials and collaborations. The net loss narrowed to $31.2 million from $33.9 million a year earlier, and cash reserves stood at $552.4 million.
Vir Biotechnology has appointed Elliott Sigal, M.D., Ph.D., to its board of directors. Dr. Sigal previously held prominent roles at Bristol-Myers Squibb, leading R&D initiatives that resulted in 14 new medicines. His extensive experience in biopharmaceuticals includes a focus on immuno-oncology and biologics. CEO George Scangos expressed enthusiasm about Dr. Sigal's leadership, citing his potential to enhance Vir's development pipeline aimed at treating infectious diseases. Vir’s current pipeline includes candidates targeting hepatitis B, SARS-CoV-2, and tuberculosis.
Vir Biotechnology, Inc. (Nasdaq: VIR) successfully closed its public offering, selling 8,214,285 shares at $42.00 each, generating gross proceeds of approximately $345.0 million. The offering included an option for underwriters to purchase an additional 1,071,428 shares. Registration for these securities became effective on July 7, 2020. Joint book-running managers included Goldman Sachs, BofA Securities, Cowen, and Barclays. The funds raised are intended to support Vir's clinical-stage pipeline focused on serious infectious diseases, including hepatitis B and SARS-CoV-2.
Vir Biotechnology, Inc. (Nasdaq: VIR) announced the pricing of an underwritten public offering of 7,142,857 shares at $42.00 each, aiming for gross proceeds of approximately $300 million. The offering is set to close on July 10, 2020, pending customary conditions. Additionally, underwriters are granted a 30-day option to buy up to 1,071,428 extra shares. Goldman Sachs, BofA Securities, Cowen, and Barclays are managing the offering. This capital is intended to bolster its pipeline targeting infectious diseases, including hepatitis B and SARS-CoV-2.
Vir Biotechnology has filed a registration statement for a proposed underwritten public offering of 6,200,000 shares of its common stock. Additionally, the underwriters may purchase up to 930,000 more shares. The offering price is yet to be determined, and is subject to market conditions. Goldman Sachs, BofA Securities, Cowen, and Barclays are the joint book-running managers for this offering. The company aims to utilize the proceeds to enhance its clinical-stage immunology initiatives targeting infectious diseases, including SARS-CoV-2 and hepatitis B.
Vir Biotechnology announced significant advancements in COVID-19 therapeutics, including promising results for the human monoclonal antibody S309, effective against SARS-CoV-2. The research published in Nature highlights that S309 neutralizes SARS-CoV-2 live virus, potentially overcoming resistance. Clinical testing is set to commence in collaboration with GlaxoSmithKline this summer. Vir's candidates, VIR-7831 and VIR-7832, show potential to address evolving coronaviruses, emphasizing a high barrier to resistance and extended half-lives, paving the way for effective COVID-19 treatments.
Vir Biotechnology (Nasdaq: VIR) reported first-quarter financial results for 2020, highlighting a revenue increase to $5.7 million from $3.7 million in Q1 2019, largely due to higher grant revenue.
However, the company experienced a net loss of $77.2 million or $0.71 per share, significantly up from a $28.7 million loss last year. R&D expenses surged to $65.0 million driven by collaborations and clinical trial costs. The company is actively advancing its COVID-19 programs with ongoing clinical trials and partnerships with major firms like GSK and Samsung Biologics.
